Clinical Trials Browser

Phase 3 × Alpelisib × 30 days × Clear all

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

Ovarian Neoplasms

NCT05038735 2026-02-20

EPIK-B5

Phase 3 Active not recruiting

Breast Neoplasms